Combining DMI and [18F]FDG-PET can complement the assessment of metabolic dysfunction-associated fatty liver disease

F]FDG-PET acquisition for assessing hepatic glucose metabolism. With its proven viability in healthy and MAFLD livers, hybrid DMI-PET imaging shows promise as a prospective non-invasive tool to improve metabolic disease characterization and support future research applications. KEY POINTS: Simultaneous DMI and [¹⁸F]FDG-PET acquisition is technically feasible on a standard PET/MR system. Hybrid DMI-PET imaging enables dual assessment of hepatic glucose transport and metabolism, offering the advantage of reduced assessment duration. High-dose glucose administration for DMI is compatible with PET imaging, thereby reducing the subject's burden and enhancing liver metabolic evaluation.